On Monday, ImmunityBio Inc (NASDAQ: IBRX) opened lower -6.26% from the last session, before settling in for the closing price of $5.27. Price fluctuations for IBRX have ranged from $1.25 to $6.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 195.19% over the past five years. Company’s average yearly earnings per share was noted 40.87% at the time writing. With a float of $136.93 million, this company’s outstanding shares have now reached $670.87 million.
Let’s look at the performance matrix of the company that is accounted for 628 employees.
ImmunityBio Inc (IBRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ImmunityBio Inc is 79.68%, while institutional ownership is 8.49%. The most recent insider transaction that took place on Jun 05 ’23, was worth 198,023. In this transaction Director of this company bought 71,915 shares at a rate of $2.75, taking the stock ownership to the 71,915 shares. Before that another transaction happened on Jun 02 ’23, when Company’s Director bought 25,000 for $2.83, making the entire transaction worth $70,700. This insider now owns 25,000 shares in total.
ImmunityBio Inc (IBRX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2023, the company posted -$0.35 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.18) by -$0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.70% during the next five years compared to 1.17% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Check out the current performance indicators for ImmunityBio Inc (IBRX). In the past quarter, the stock posted a quick ratio of 5.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5369.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.13, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
ImmunityBio Inc (NASDAQ: IBRX) saw its 5-day average volume 4.24 million, a positive change from its year-to-date volume of 4.05 million. As of the previous 9 days, the stock’s Stochastic %D was 19.58%. Additionally, its Average True Range was 0.54.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 50.00%, which indicates a significant increase from 13.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.19% in the past 14 days, which was lower than the 116.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.15, while its 200-day Moving Average is $3.40. Nevertheless, the first resistance level for the watch stands at $5.22 in the near term. At $5.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.65. If the price goes on to break the first support level at $4.79, it is likely to go to the next support level at $4.64. Assuming the price breaks the second support level, the third support level stands at $4.36.
ImmunityBio Inc (NASDAQ: IBRX) Key Stats
There are currently 677,003K shares outstanding in the company with a market cap of 3.33 billion. Presently, the company’s annual sales total 620 K according to its annual income of -583,200 K. Last quarter, the company’s sales amounted to 140 K and its income totaled -233,390 K.
